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Pre-exposure prophylaxis (PrEP), a WHO-recommended HIV prevention method for people
at high risk for acquiring HIV, is being increasingly implemented in many countries. Setting
programmatic targets, particularly in generalised epidemics, could incorporate estimates of
the size of the population likely to be eligible for PrEP using incidence-based thresholds. We
estimated the proportion of men and women who would be eligible for PrEP and the number
of HIV infections that could be averted in Malawi, Mozambique, and Zambia using prioritisa-
tion based on age, sex, geography, and markers of risk.
Methods and findings
We analysed the latest nationally representative Demographic and Health Surveys (DHS) of
Malawi, Mozambique, and Zambia to determine the proportion of adults who report beha-
vioural markers of risk for HIV infection. We used prevalence ratios (PRs) to quantify the
association of these factors with HIV status. Using a multiplier method, we combined these
proportions with the number of new HIV infections by district, derived from district-level mod-
elled HIV estimates. Based on these numbers, different scenarios were analysed for the
minimum number of person-years on PrEP needed to prevent 1 HIV infection (NNP).
An estimated total of 38,000, 108,000, and 46,000 new infections occurred in Malawi,
Mozambique, and Zambia in 2016, corresponding with incidence rates of 0.43, 0.63, and
0.57 per 100 person-years. In these countries, 9%–20% of new infections occurred among
people with a sexually transmitted infection (STI) in the past 12 months and 40%–42%
among people with either an STI or a non-regular sexual partner (NP) in the past 12 months
(STINP). The models estimate that around 50% of new infections occurred in districts with
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incidence rates�1.0% in Mozambique and Zambia and�0.5% in Malawi. In Malawi,
Mozambique, and Zambia, 35.1%, 21.9%, and 12.5% of the population live in these high-
incidence districts. In the most parsimonious scenario, if women aged 15–34 years and men
20–34 years with an STI in the past 12 months living in high-incidence districts were to take
PrEP, it would take a minimum of 65.8 person-years on PrEP to avert 1 HIV infection per
year in Malawi, 35.2 in Mozambique, and 16.4 in Zambia. Our findings suggest that 3,300,
5,200, and 1,700 new infections could be averted per year in the 3 countries, respectively.
Limitations of our study are that these values are based on modelled estimates of HIV inci-
dence and self-reported behavioural risk factors from national surveys.
Conclusions
A large proportion of new HIV infections in these 3 African countries were estimated to occur
among people who had either an STI or an NP in the past year, providing a straightforward
means to set PrEP targets. Greater prioritisation of PrEP by district, sex, age, and beha-
vioural risk factors resulted in lower NNPs thereby increasing PrEP cost-effectiveness, but
also diminished the overall impact on reducing new infections
Author summary
Why was this study done?
• WHO recommends oral pre-exposure prophylaxis (PrEP) for people at substantial risk
of HIV to prevent HIV acquisition, currently defined as 3% or higher per annum.
• Prioritising those at “substantial risk” increases the cost-effectiveness of PrEP.
• Setting programmatic targets to estimate the number of people who are at substantial
risk and who could benefit from PrEP is challenging.
• This study was done to provide a straightforward approach, with some country exam-
ples, to estimate PrEP need and to help prioritise the offer of PrEP in settings with high
HIV prevalence.
What did the researchers do and find?
• We used modelled subnational age- and sex-specific HIV incidence estimates with pop-
ulation survey data from 3 countries to generate estimates of the increase in risk for peo-
ple with behaviours that can be reported programmatically.
• Applying both these estimates together enabled us to calculate how many people fall
into different broad categories of substantial HIV risk and therefore the sizes of poten-
tial populations that could benefit from PrEP.
• It also allows estimating the likely impact that PrEP could have on reducing new HIV
infections if prioritised in this way.
PLOS MEDICINE PrEP need and impact for programmatic prioritization in three African countries
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003482 January 11, 2021 2 / 16
(USAID, www.usaid.gov) under the U.S.
President’s Emergency Plan for AIDS Relief
(PEPFAR, https://www.state.gov/pepfar/). The
grant supported SD, RB, and DS. DC was
previously employed by USAID for a period of time
during which this study was conducted. The
contents in this article are the sole responsibility of
the authors, and do not necessarily reflect the
views of WHO, USAID, PEPFAR or the United
States Government. The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: AIS, AIDS Indicator Surveys; ART,
antiretroviral therapy; COVID-19, Coronavirus
disease 2019; DHS, Demographic and Health
Surveys; NP, non-regular sexual partner; NNP,
number of person-years on PrEP needed to
prevent 1 HIV infection; PLHIV, people living with
HIV; PR, prevalence ratio; PrEP, pre-exposure
prophylaxis; STI, sexually transmitted infection;
STINP, sexually transmitted infection or non-
regular partners; TDF, tenofovir disoproxil
fumarate; UNAIDS, Joint United Nations
Programme on HIV/AIDS.
• We found that the most focused approach of offering PrEP to women aged 15–34 years
and men 20–34 years, with a sexually transmitted infection (STI) in the past 12 months
in high-incidence districts, lowered the number of person-years on PrEP needed to
avert 1 HIV infection. A less prioritised approach, encouraging broader use of PrEP,
would have a greater impact on population-level reduction of HIV infections, but will
cost more.
What do these findings mean?
• For comparatively more expensive prevention interventions like PrEP, prioritising fac-
tors such as geography, age, sex, and sexual behaviour allows subgroups with high aver-
age HIV incidence to be identified.
• As PrEP is scaled up, policy makers and funders will have to make careful decisions that
balance costs, impact, demand, and the basic rights of individuals to access highly effec-
tive prevention tools.
Introduction
In 2019, there were an estimated 38.0 million people living with HIV (PLHIV) and 1.7 million
new HIV infections worldwide, far distant from the Joint United Nations Programme on
HIV/AIDS (UNAIDS) global target of fewer than 500,000 new infections by 2020 [1,2]. Eastern
and southern Africa alone contributed about 43% of global new HIV infections and 53% of
worldwide prevalent HIV infections in 2019 [2]. Women aged 15 to 24 years old who comprise
just 10% of the population in southern and eastern Africa, contributed 26% of new infections
in 2019 [3]. Reducing new infections will require strengthening and scaling up a combination
of effective HIV prevention strategies, identifying people with undiagnosed HIV, and expand-
ing treatment coverage.
Pre-exposure prophylaxis (PrEP) is an effective HIV prevention method that entails the use
of oral daily tenofovir disoproxil fumarate (TDF)-containing antiretrovirals by HIV–negative
individuals at substantial risk to prevent HIV acquisition [4,5]. PrEP has been shown to reduce
the risk of contracting HIV in trials by up to 97% in men and transgender women both of
whom have sex with men [6]. PrEP has also been shown in trials to be highly effective in reduc-
ing HIV acquisition in heterosexual men and women [7]. WHO and UNAIDS estimated that
PrEP may be cost-effective especially when HIV incidence in subpopulations exceeds 3 per
100 person-years in the absence of PrEP and referred to this level of incidence as “substantial”
risk [8]. Others have estimated this incidence threshold to be higher and influenced by overall
prevention expenditure [9], and other countries such as the United States have moved ahead
with lower thresholds [10]. These thresholds need to be interpreted in the context of risks that
may vary considerably from month to month [11]. High levels of HIV incidence continue to
be reported in the general population within certain communities in eastern and southern
Africa where this threshold may be relevant [8,12,13]. Adherence to the prescribed PrEP regi-
men is critical for effectiveness [14,15]. Although the cost of PrEP is lower than lifelong antire-
troviral therapy (ART), it is a comparatively more expensive preventive intervention
compared to male and female condoms or voluntary medical male circumcision.
PLOS MEDICINE PrEP need and impact for programmatic prioritization in three African countries
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003482 January 11, 2021 3 / 16
Establishing the size of the population who are likely to be at “substantial” risk in general
population settings (outside of key populations where HIV incidence remains higher than the
overall population) could assist programmes in setting annual targets for PrEP drug procure-
ment and delivery of PrEP services. We estimated the proportion of men and women who
would be eligible for PrEP and the number of HIV infections that could be averted in Malawi,
Mozambique, and Zambia in different scenarios using prioritisation based on geography, age,
sex, and survey markers of HIV risk.
Methods
We used 2 sources of data to calculate the size of the population at risk of HIV and in need of
PrEP using different prioritisation criteria. We analysed the latest Demographic and Health
Surveys (DHS) to determine the effect of association between certain behavioural factors and
HIV status and the proportion of people who reported these risk factors. We also used the
2016 modelled estimates (HIVE-Map Geospatial Model) for the number of new HIV infec-
tions nationally as well as disaggregated HIV incidence by age, sex, and district for each coun-
try [16,17]. Three countries—Malawi, Mozambique, and Zambia—were selected for analysis
because all 3 had both recent DHS including HIV testing (Malawi (DHS 2015/2016), Mozam-
bique (AIDS Indicator Surveys (AIS) 2015), Zambia (DHS 2013/2014)) and 2016 district-level
HIV incidence estimates (HIVE estimates) available.
Demographic and health surveys
DHS are nationally representative household surveys that provide data for a wide range of
indicators in the areas of population, health, and nutrition. In some DHS, HIV testing is
included. AIS are a special subtype of DHS focusing on indicators for the effective monitoring
of national HIV/AIDS programs [18].
We chose known risk factors for incident HIV infections that were available in DHS data-
sets. These were reporting symptoms of a sexually transmitted infection (STI) in the past 12
months or have non-regular sexual partners (NPs) in the past 12 months. We categorised a
response of “yes” to any of the following 3 questions as having had an STI in the past 12
months: “Have you had any STI in last 12 months?,” “Have you had a genital sore/ulcer in last
12 months?,” and “Have you had a genital discharge in last 12 months?.” People who reported
having at least 1 sexual partner who was not a spouse or cohabiting partner were considered to
have had an NP. Out of these questions, we created 2 risk variables: (A) people who reported
an STI in the past 12 months (STI); and (B) people who reported either an STI or at least 1 NP
in the past 12 months (sexually transmitted infection or non-regular partners (STINP)).
To determine the association between the behavioural factors and HIV prevalence, we cal-
culated prevalence ratios (PRs) by 5-year age groups and sex (PRasr). For this analysis, we com-
bined the datasets of all 3 countries in order to increase the number of cases in each group. If
less than 50 weighted cases occurred in a specific age group, this age group was merged with
the next older one. For the variable STI in the past 12 months, the age groups 15 to 19 and 20
to 24 years were combined for women, and the age groups 15 to 19, 20 to 24, and 25 to 29
years were combined for men; for the variables STINP (STI or NP) in the past 12 months, for
men, the age groups 15 to 19 years and 20 to 24 years were combined (S1A and S1B Tables).
Geospatial incidence estimates
The HIVE-Map Geospatial Model estimates the distribution of new HIV infections, PLHIV,
and ART coverage at district level and by age and sex [16,17]. The model uses facility level
prevalence among pregnant women attending antenatal care, facility-level number of people
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on antiretroviral treatment, cluster-level survey data on prevalence among adults, 5 × 5 km
demographic data from AfriPop, and a suite of 5 ×5 km resolution geospatial covariates that
are predictive of spatial variation in HIV risk. Pixel-level predictions are scaled within each
country or administrative unit to ensure consistency with national Spectrum estimates created
in 2016 and used for national planning. District-level estimates of PLHIV, new infections, and
ART coverage were produced by sex and age group for 10 countries in late 2017 and early
2018 [16,17].
HIV incidence calculation and number of person-years on PrEP needed to
prevent one HIV infection (NNP)
We assumed that all new HIV infections among adults occurred among sexually active people,
since it is the predominant mode of transmission in African countries [19]. Sexually active was
defined as people reporting having had sex in the past 12 months.
For the calculation of the number of people at risk of HIV infection by age, sex, and district
(Rasrd), the proportion of people with STI or STINP in the past 12 months by age and sex (Pasr)
was multiplied by the number of people by age, sex, and district (Nasd) in each country. The
following formula was used:
Rasrd ¼ Pasr �Nasd:
We then combined the PRs and the number of people with the risk factor using the follow-
ing formula:
Iasrd ¼ Iasd �
ðRasrd � PRasrÞ
ðQasrd þ ðRasrd � PRasrÞÞ
Iasrd: Incident HIV infections in the group with the risk factor, by age, sex, and district
Iasd: Incident HIV infections in the country, by age, sex, and district
Rasrd: Number of people with the risk factor, by age, sex, and district
Qasrd: Number of people without the risk factor, by age, sex, and district
PRasr: Prevalence ratio by age, sex, and risk factor
Based on Iasrd, we analysed different scenarios for HIV incidence as well as the number of
person-years on PrEP needed to prevent 1 HIV infection (NNP). We assumed 100% drug effi-
cacy. In a more realistic setting, allowing for factors such as low coverage, low uptake, and
high discontinuation that occur during service delivery, we assumed a PrEP effectiveness of
50% with an uncertainty interval from 25% to 75% [15]. The scenarios for PrEP provision
were the following: all adults (scenario 1), by age group (scenario 2), by district HIV incidence
(scenario 3), and by age, sex, and district HIV incidence (scenario 4). For each scenario, data
are additionally presented for the subset of people with STINP and the people with STI in the
past 12 months.
For the scenarios that included HIV incidence by district, cutoffs were chosen to define
high-incidence districts as those where approximately 50% of all new infections occurred, mid-
dle incidence districts where approximately 25% of new infections occurred, and low inci-
dence districts had <25% of new infections. The cutoffs were then rounded to the nearest 10th
of a percent. The district incidence rate cutoffs were 1% and 0.5% for Zambia and Mozam-
bique and 0.5% and 0.3% for Malawi.
All analyses were prespecified and were run using Microsoft Excel and R version 3.5.1. We
did not have a protocol or prespecified analysis plan for this study. Reporting followed the
RECORD checklist (S2 Table).
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Ethical approval
All the utilised DHS and AIS datasets are publicly available. The DHS programme data are de-
identified before made available to the public. No data on individual participants was pre-
sented. Therefore, this work did not require ethical approval.
Results
In the year 2016, an estimated total number of 38,000 adults (aged 15 years and older) were newly
infected with HIV in Malawi, 108,000 in Mozambique, and 46,000 in Zambia. HIV incidence
derived from the HIVE models was 0.41% in Malawi, 0.56% in Mozambique, and 0.54% in Zam-
bia. In all 3 countries, women were more likely to get infected with HIV, accounting for 56%,
58%, and 57% of all new infections in Malawi, Mozambique, and Zambia. HIV prevalence ranged
from 7.9% (95% CI 6.2 to 8.0) among men in Malawi to 14.4% (95% CI 13.7 to 17.2) among
women in Zambia. In all 3 countries, HIV prevalence was higher among women than men.
The prevalence of reported STIs across all 3 countries ranged from 3.8% to 13.6% and was
highest in Malawi (Table 1). The proportion of people who reported either an STI or had NPs
in the past 12 months was similar across the 3 countries (range 23.5 to 27.5%) and was higher
among men than women. In total numbers, in Malawi, Mozambique, and Zambia, 2.6, 5.3,
and 2.2 million people were categorised as STINP in the past 12 months. Of those, 1.1, 1.2, and
0.4 million people only had an STI.
In all 3 countries combined, HIV prevalence among women with an STI in the past 12
months was 22.9% compared to 14.6% among women without STI. Among men with STI in
the past 12 months, HIV prevalence was 16.6% compared to 10.3% among men without an
STI. The PRs showed that women had an increased probability of being infected with HIV if
they were in the category STI or STINP regardless of age (PR range for STI: 1.40 to 1.78; PR
range for STINP: 1.53 to 2.14). For men, the same was true for those with an STI in the past 12
months (range: 1.64 to 1.85) and for STINP for men aged�25 years (PR range 1.31 to 1.75),
but the association was reversed in younger men aged 15 to 24 years (S1 and S2 Tables).
Scenario 1: New HIV infections by sex
In Malawi, Mozambique, and Zambia, 40%, 42%, and 40% of all new infections occurred
among people in the category STINP. This corresponds with 15,000, 45,000, and 18,000 new
Table 1. Number of new HIV infections, incidence, prevalence, and proportion of people with an STI or NP in the past 12 months in Malawi, Mozambique, and
Zambia.
Country Population 15 years




















Malawi All 9.9 38,000 0.43 9.8% 26.2% 18.2% 11.3%
Females 5.1 21,000 55% 0.49 11.7% 21.9% 10.0% 13.6%
Males 4.8 17,000 45% 0.37 7.9% 31.2% 26.4% 8.6%
Mozambique All 19.3 108,000 0.63 10.7% 27.5% 25.5% 6.3%
Females 9.9 63,000 58% 0.72 12.5% 20.8% 16.4% 6.2%
Males 9.3 46,000 43% 0.54 8.8% 37.6% 34.6% 6.5%
Zambia All 9.2 46,000 0.57 12.2% 23.5% 21.3% 4.3%
Females 4.7 27,000 57% 0.67 14.4% 17.4% 14.5% 3.8%
Males 4.6 20,000 43% 0.48 10.0% 30.4% 28.0% 5.0%
�HIV incidence and prevalence measures were obtained from HIVE modelled estimates.
HIVE, geospatial HIV estimates; NP, non-regular sexual partner; STI, sexually transmitted infection; STINP, sexually transmitted infection or non-regular partners.
https://doi.org/10.1371/journal.pmed.1003482.t001
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infections. Proportionally, markedly more HIV infections occurred among men than women
in the category STINP in the past 12 months in Mozambique (51% among men and 38%
among women) (Table 2). For people with an STI alone, a different picture was seen. In
Mozambique and Zambia, there was no major difference between men and women, whereas
in Malawi, proportionally more infections occurred among women with an STI in the past 12
months (Malawi: 22% versus 16%; Table 2). Using STI in the past 12 months as a marker of
risk, HIV incidence exceeded 1% only among women in Mozambique and Zambia.
Scenario 2: New HIV infections by sex and age
In all 3 countries, more than 3 quarters of all new infections occurred among men and women
between the age of 15 and 34 years (Table 2). For women, the age group of 15 to 34 years was
most affected by HIV; for men, the most affected age groups were 20 to 34 years, likely because
sexual debut is usually later than among women. In these age groups, the HIV incidence is
higher for men and women than in older age groups (Table 2).
Scenario 3: New HIV infections by district incidence
In Malawi, not a single district had an incidence�1.0%, but 8 out of 28 districts had incidence
rates�0.5%. Approximately 3.5 million people reside in these districts. In Mozambique, 62/
159 districts had an incidence�1.0% where more than 4.2 million people live. In Zambia, the
epidemic is concentrated on fewer districts (55/103) in which 3.2 million people live. The aver-
age HIV incidence in districts where around half of all HIV infections occur is 0.66% in
Malawi, 1.26% in Mozambique, and 2.53% in Zambia. The HIV incidence among people in
the category STINP in the past 12 months in these high-incidence districts was 1.05% in
Malawi, 1.84% in Mozambique, and 4.32% in Zambia. Among people with STI in the past 12
months, the respective HIV incidence rates were 1.21% in Malawi, 2.40% in Mozambique, and
4.93% in Zambia (Fig 1).
Scenario 4: New HIV infections by sex, age, and district
In Malawi, Mozambique, and Zambia, 44%, 36%, and 42% of all new infections occurred
among women aged 15 to 34 years and men aged 20 to 34 years who lived in high-incidence
districts. These proportions represent 17,000, 39,000, and 19,000 new HIV infections
(Table 2). By selecting men and women in these age groups who lived in high-incidence dis-
tricts and who had an STI in the past 12 months, the HIV incidence increased to 1.52% in
Malawi, 2.84% in Mozambique, and 6.10% in Zambia (Table 2, Fig 1). In all 3 countries, the
HIV incidence was higher among young women than among young males.
In summary, in Malawi, there was no district, age group, or population with behavioural
risk factors that had an average HIV incidence above the�3% PrEP threshold. In
Table 2. New HIV infections and HIV incidence by scenario and priority population.
Country Sex Age group District incidence (%) New HIV infections Proportion of new infections HIV incidence (%) HIV incidence (%)
Sex in the past 12 months STINP in the past 12 months STI in the past 12 months Sex in the past 12 months STINP STI
Scenario 1 Malawi All 38,000 100% 40% 20% 0.41 0.53 0.64 0.75
Females 21,000 100% 41% 22% 0.49 0.66 0.93 0.82
Males 17,000 100% 39% 16% 0.34 0.43 0.45 0.66
Mozambique All 108,000 100% 42% 12% 0.56 0.69 0.82 1.08
Females 63,000 100% 38% 11% 0.63 0.84 1.18 1.20
Males 46,000 100% 49% 13% 0.49 0.56 0.62 0.97
Zambia All 46,000 100% 40% 9% 0.54 0.70 0.90 1.05
Females 26,000 100% 39% 7% 0.66 0.88 1.48 1.27
Males 20,000 100% 41% 10% 0.43 0.56 0.60 0.90
(Continued)
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Table 2. (Continued)
Country Sex Age group District incidence (%) New HIV infections Proportion of new infections HIV incidence (%) HIV incidence (%)
Sex in the past 12 months STINP in the past 12 months STI in the past 12 months Sex in the past 12 months STINP STI
Scenario 2 Malawi All 15–19 5,900 16% 9% 3% 0.30 0.71 0.54 0.82
20–24 9,500 25% 11% 5% 0.55 0.69 0.67 0.93
25–29 8,800 24% 10% 5% 0.59 0.65 0.90 0.93
30–34 5,600 15% 6% 3% 0.51 0.55 0.82 0.78
35–39 3,600 10% 3% 2% 0.39 0.43 0.59 0.56
40–49 3,300 9% 2% 2% 0.27 0.31 0.41 0.44
50+ NA NA NA NA NA NA NA NA
15–34 29,800 80% 35% 16% 0.47 0.65 0.69 0.88
Females 15–19 5,200 25% 13% 5% 0.52 1.16 1.22 1.43
20–24 5,600 27% 11% 6% 0.65 0.79 1.06 1.01
25–29 4,400 21% 8% 5% 0.58 0.67 1.01 0.91
30–34 2,600 12% 5% 3% 0.47 0.54 0.83 0.69
35–39 1,600 8% 3% 2% 0.35 0.41 0.59 0.48
40–49 1,500 7% 2% 2% 0.25 0.32 0.44 0.41
50+ NA NA NA NA NA NA NA NA
15–34 17,800 85% 36% 19% 0.56 0.78 1.06 0.98
Males 15–19 800 5% 3% 1% 0.08 0.2 0.13 0.23
20–24 3,800 23% 11% 4% 0.44 0.59 0.42 0.79
25–29 4,400 27% 12% 5% 0.59 0.64 0.84 0.95
30–34 3,000 18% 7% 3% 0.54 0.57 0.82 0.96
35–39 2,000 12% 3% 2% 0.43 0.45 0.59 0.69
40–49 1,700 11% 2% 1% 0.30 0.31 0.38 0.51
50+ 800 5% 1% 1% 0.13 0.14 0.17 0.23
20–34 11,200 68% 30% 12% 0.52 0.60 0.62 0.90
Mozambique All 15–19 14,000 13% 7% 1% 0.37 0.60 0.54 0.87
20–24 30,300 28% 13% 4% 0.9 1.00 0.97 1.42
25–29 24,100 22% 10% 3% 0.88 0.96 1.23 1.39
30–34 14,700 14% 6% 2% 0.69 0.75 1.07 1.12
35–39 9,500 9% 3% 1% 0.51 0.57 0.76 0.77
40–49 10,100 9% 3% 1% 0.40 0.46 0.61 0.70
50+ 5600 5% 1% 0% 0.20 0.29 0.3 0.36
15–34 83,100 77% 36% 10% 0.69 0.84 0.89 1.25
Females 15–19 9,800 16% 8% 2% 0.52 0.8 0.94 1.11
20–24 18,600 30% 12% 4% 1.1 1.28 1.71 1.69
25–29 13,200 21% 8% 3% 0.96 1.13 1.57 1.49
30–34 7,400 12% 4% 1% 0.69 0.78 1.19 1.03
35–39 4,700 8% 2% 1% 0.50 0.60 0.84 0.70
40–49 5,700 9% 3% 1% 0.41 0.52 0.72 0.71
50+ 3,400 5% 1% 0% 0.21 0.4 0.41 0.38
15–34 49,000 78% 32% 10% 0.81 1.02 1.34 1.40
Males 15–19 4,200 9% 7% 1% 0.22 0.39 0.33 0.58
20–24 11,800 26% 14% 4% 0.69 0.74 0.63 1.15
25–29 10,800 24% 14% 4% 0.79 0.81 1.05 1.29
30–34 7,200 16% 7% 2% 0.68 0.71 0.98 1.2
35–39 4,800 11% 3% 1% 0.52 0.53 0.7 0.85
40–49 4,400 10% 2% 1% 0.38 0.4 0.49 0.68
50+ 2,300 5% 1% 1% 0.19 0.21 0.25 0.35
20–34 29,800 65% 34% 10% 0.72 0.76 0.82 1.21
Zambia All 15–19 8,800 19% 12% 1% 0.49 1.32 1.02 1.62
20–24 10,600 23% 10% 2% 0.71 0.98 0.87 1.24
25–29 8,900 20% 8% 2% 0.71 0.78 1.06 1.20
30–34 6,600 15% 5% 1% 0.61 0.65 1.01 1.06
35–39 4,500 10% 3% 1% 0.49 0.53 0.75 0.79
40–49 4,300 10% 2% 1% 0.36 0.41 0.56 0.66
50+ NA NA NA NA NA NA NA NA
15–34 34,900 77% 35% 7% 0.62 0.90 0.98 1.24
Females 15–19 7,200 28% 17% 2% 0.79 1.94 1.95 2.45
20–24 6,700 26% 11% 2% 0.89 1.16 1.59 1.61
25–29 4,700 19% 5% 2% 0.75 0.83 1.44 1.31
30–34 3,200 12% 3% 1% 0.58 0.64 1.17 0.96
35–39 2,000 8% 2% 1% 0.43 0.48 0.8 0.66
40–49 1,700 7% 1% 1% 0.29 0.37 0.61 0.57
50+ NA NA NA NA NA NA NA NA
15–34 21,800 86% 36% 6% 0.77 1.08 1.65 1.54
Males 15–19 1,600 8% 5% 1% 0.18 0.54 0.33 0.62
20–24 3,900 20% 10% 3% 0.53 0.78 0.54 1.00
25–29 4,100 21% 11% 2% 0.66 0.74 0.92 1.12
30–34 3,500 17% 7% 2% 0.63 0.67 0.93 1.13
35–39 2,500 13% 4% 1% 0.55 0.57 0.72 0.88
40–49 2,600 13% 3% 1% 0.41 0.44 0.53 0.73
50+ 1,600 8% 1% 1% 0.23 0.25 0.3 0.42
20–34 11,500 58% 28% 7% 0.60 0.73 0.73 1.08
(Continued)
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Table 2. (Continued)
Country Sex Age group District incidence (%) New HIV infections Proportion of new infections HIV incidence (%) HIV incidence (%)
Sex in the past 12 months STINP in the past 12 months STI in the past 12 months Sex in the past 12 months STINP STI
Scenario 3 Malawi �1.0 0 - - - - - - -
0.5–0.99 21,000 56% 23% 11% 0.66 0.86 1.05 1.21
<0.5 16,000 44% 18% 9% 0.28 0.36 0.44 0.51
Mozambique �1.0 53,000 49% 21% 6% 1.26 1.56 1.84 2.40
0.5–0.99 25,000 23% 10% 3% 0.68 0.83 0.98 1.29
<0.5 31,000 28% 12% 3% 0.27 0.33 0.40 0.52
Zambia �1.0 27,000 59% 24% 5% 2.53 3.30 4.32 4.93
0.5–0.99 13,000 28% 12% 2% 0.69 0.91 1.18 1.35
<0.5 5,800 13% 5% 1% 0.11 0.14 0.18 0.21
Scenario 4 Malawi All � �0.5 17,000 44% 19% 9% 0.87 1.12 1.33 1.52
Females 15–34 10,000 48% 20% 11% 0.90 1.24 1.70 1.56
Males 20–34 6,300 38% 17% 7% 0.84 0.96 0.99 1.44
Mozambique All � �1.0 39,000 36% 16% 5% 1.67 1.95 2.25 2.84
Females 15–34 24,000 39% 16% 5% 1.74 2.19 2.86 3.02
Males 20–34 15,000 32% 17% 5% 1.57 1.65 1.77 2.63
Zambia All � �1.0 19,000 43% 19% 4% 3.32 4.37 5.29 6.10
Females 15–34 13,000 50% 21% 4% 3.64 5.10 7.80 7.28
Males 20–34 6,700 34% 17% 4% 2.86 3.45 3.48 5.11
� Women aged 15–34 years and men aged 20–34 years.
Scenario 1: no disaggregation by age group or district.
Scenario 2: disaggregation by age group.
Scenario 3: disaggregation by district incidence.
Scenario 4: disaggregation by district incidence and high-incidence age group (females 15–34 years, men 20–34 years).
NA, not applicable; STI, sexually transmitted infection; STINP, sexually transmitted infection or non-regular partners.
https://doi.org/10.1371/journal.pmed.1003482.t002
Fig 1. HIV incidence and proportion of new HIV infections potentially averted
y
by scenario and priority population. Scenario 1: all people, scenario 2: people
aged 15–34 years, scenario 3: people living in high-incidence districts, and scenario 4: women aged 15–34 years and men aged 20–34 years who live in high-incidence
districts. STI, sexually transmitted infection.
y
Proportion of new HIV infections that could be averted are shown as numbers in boxes.
https://doi.org/10.1371/journal.pmed.1003482.g001
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Mozambique, young women (aged 15 to 34 years) who lived in high-incidence districts and
who had an STI in the past 12 months are above the 3% threshold for PrEP. Due to the high
overall incidence in Zambia, different subpopulations could be prioritised for PrEP depending
on resources. The most infections potentially averted could be obtained by encouraging PrEP
use by all sexually active adults living in high-incidence districts. This would mean 805,000
person-years of PrEP being used and thereby potentially averting up to 26,000 new HIV infec-
tions (Fig 2). If PrEP were prioritised only to certain age groups (females 15 to 34 years and
males 20 to 34 years), it would take 545,000 person-years of PrEP to potentially avert up to
19,000 infections. Focusing instead on only younger people who live in high-incidence dis-
tricts and who were categorised as STINP would mean 165,000 person-years of PrEP to avert
up to 8,700 new HIV infections. Focusing on younger people who had an STI in the past 12
months would mean that 28,000 person-years on PrEP would need to be taken in order to
avert up to 1,700 new HIV infections. The proportion of infections potentially averted out of
all new HIV infections with this focused approach would be very small (4%) and if a PrEP
effectiveness of 50% is applied, would be only half of these infections (Table 3).
Discussion
Decisions on where and to whom to offer PrEP as a priority are complex and need to consider
estimated numbers of individuals at risk of HIV, cost, equity, and other factors. Combining
All people
People with STI or
non−regular partners
in past 12 months
People with STI























































Fig 2. NNP by scenario and priority population. Scenario 1: all people, scenario 2: people aged 15–34 years, scenario 3: people living in high-incidence districts, and
scenario 4: women aged 15–34 years and men aged 20–34 years who live in high-incidence districts. NNP, number of person-years on PrEP needed to prevent 1 HIV
infection; PrEP, pre-exposure prophylaxis; STI, sexually transmitted infection.
https://doi.org/10.1371/journal.pmed.1003482.g002
PLOS MEDICINE PrEP need and impact for programmatic prioritization in three African countries
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003482 January 11, 2021 10 / 16
the geospatial mapping of HIV incidence with age, sex, and easily accessible markers of beha-
vioural risk more precisely identified subpopulations with likely high HIV incidence which
includes many of those who may benefit from PrEP and would theoretically inform a cost-
effective way of delivering PrEP in Malawi, Mozambique, and Zambia. Our findings from
Malawi, Mozambique, and Zambia showed that even in settings with high HIV prevalence, the
numbers needed to prevent 1 infection are high, but decline quickly if approaches that use age,
sex, and geospatial risk are considered in program planning. The average HIV incidence in
districts where half of all infections occurred varied considerably (0.7%, 1.3%, and 4.9%,
respectively) and increased when combined with sex, age, and STIs to 1.5%, 2.8%, and 6.1% in
each country. In Malawi, no combination of district, sex, age, and risk group resulted in an
incidence above the 3% incidence threshold suggested by WHO and UNAIDS as being poten-
tially cost-effective for PrEP. Using this approach to PrEP prioritisation, the lowest numbers of
person-years of PrEP needed to prevent 1 infection were 33.1 in Mozambique and 16.4 in
Zambia.
Considering geography is critical in the prioritisation of PrEP services since HIV prevalence
and incidence vary considerably in countries with generalised epidemics [20–22]. Our analysis
showed that approximately half of new infections occurred in districts with overall HIV inci-
dence rates�1.0% in Mozambique and Zambia and�0.5% in Malawi. Zambia was the only
country which had 7 districts over the 3% incidence threshold. In all 3 countries, over 3 quar-
ters of new infections occurred among men and women between the age of 15 and 34 years,
with few in the 15 to 19 years age group. Using these sex- and age-specific data further identi-
fied subpopulations with higher HIV incidence; even so, Zambia remained the only country
which had a 3% incidence in any subgroup; Mozambique reached nearly 2% for women.
Therefore, at a population level, further prioritisation of PrEP services required the inclusion
of individual sexual behaviour.
Focusing support at the individual level based on age, sex and risk behaviour is commonly
used to offer PrEP in clinical settings [23–25] and often centres on a history of sex without
condoms, partner HIV status, and STIs. Our analyses using the magnitude of the association
between behavioural risk factors for HIV from survey data showed that having had an STI in
Table 3. Scenarios identifying priority populations with HIV incidence�3% and HIV infections that potentially could be averted.
Malawi Mozambique Zambia
Population for prioritisation None
Sex - Females Both sexes Females Both sexes Both sexes Both sexes
Age group (years) - 15–34 15+ 15+ 15/20–34 15/20–34 15/20–34
District incidence - �1% �1% �1% �1% �1% �1%
Risk factor - STI Sexually active Sexually active Sexually active STINP STI
Priority population size 0 99,000 805,000 360,000 545,000 165,000 28,000
HIV infections� 0 3,000 26,000 15,000 19,000 8,700 1,700
HIV incidence - 3.0% 3.3% 4.1% 4.4% 5.3% 6.1%
NNP��� (100% efficacy) - 33.1 30.3 24.2 22.9 18.5 16.4















�Occurring in the priority population.
��HIV infections that could be averted if 50% [25%–75%] of all people in the priority population would initiate and adhere to PrEP.
���
NNP, number of person-years on PrEP needed to prevent 1 HIV infection.
PrEP, pre-exposure prophylaxis.
https://doi.org/10.1371/journal.pmed.1003482.t003
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the past 12 months and having an NP would serve as good markers of HIV “substantial risk”
in districts where the background incidence of HIV was already moderately high. Combining
these factors together led to the identification of multiple age-, sex-, and location-specific sub-
populations that are likely to include most people who are at substantial risk in both Mozam-
bique and Zambia. These estimates of PrEP “need” could be used as an upper bound of a PrEP
target since offering PrEP outside these bounds would be expensive. In Malawi, no combina-
tion of district, sex, age, and risk group resulted in an incidence above 3%. However, in
Malawi, and indeed in most countries, there will be individuals who may benefit from PrEP
who were not considered in our approach. Focusing on key populations (sex workers, men
who have sex with men, transgender people, prisoners, and people who use/inject drugs) or
age- and sex-specific groups with known high HIV incidence and prevalence would prevent
HIV infections [26]. As has been shown in Australia, the UK, and the US, where HIV preva-
lence is comparatively low and infections concentrated in key populations, specifically men
who have sex with men, the greatest declines in new diagnoses among priority populations
have been seen where PrEP has been used alongside expanded access and coverage of ART
[27–29].
Finding a balance between impact and cost is a challenge in all areas of public health and
particularly so for comparatively more expensive prevention interventions such as PrEP. In
our scenarios, focusing on only a part of the total population, the numbers of person-years of
PrEP to prevent 1 HIV infection ranged from 33 to 16 with the largest number of HIV infec-
tions potentially averted occurring if PrEP was offered to all sexually active adults living in
high-incidence districts. Yet offering PrEP to such large numbers of people may be cost pro-
hibitive in many settings. Conversely, while increasing the number of risk factors considered
(geography, age, sex, and behaviour) for a focused approach increases the estimated HIV inci-
dence and therefore the cost-effectiveness in the subpopulation being considered, it simulta-
neously decreases the number of infections potentially averted. Therefore, PrEP targets based
on a very focused combination of factors may be too small to achieve greater public health
impact. Such a target may however provide a pragmatic approach for early target setting dur-
ing PrEP roll out at a national/subnational level, particularly as our findings show a larger pro-
portion of new HIV infections occurred among people with an STI or NPs in the past 12
months. While focused approaches may assist policy makers in prioritising resources, from a
societal perspective, efforts to increase awareness and demand for PrEP more broadly through
positive messaging for anyone in need have the benefit of reducing stigma and barriers to
access that may occur if PrEP is perceived to be only for certain age groups, locations, or key
populations [30].
The prevalence of reported STIs across all 3 countries ranged from 3.8% to 13.6% and was
highest in Malawi. As etiological diagnosis of STIs is not currently available in many low- and
middle-income settings, and syndromic approaches are more commonly used, this is likely to
have limitations. Nevertheless, assessing history of an STI is a useful simple screen indicating
higher HIV risk. Identifying people with an STI could be more easily achieved in a clinical set-
ting and integrating PrEP into existing services where some level of STI management is offered
(e.g., sexual and reproductive health services); PrEP users are also noted to have high rates of
STIs [31–33]. Since the estimate includes all individuals with these risk factors, some of whom
will not present to clinical services and will be difficult to identify and offer PrEP to, these tar-
gets will be aspirational.
Although this multilevel approach is needed to prioritise resources for PrEP at a subna-
tional level, a large number of new infections may occur outside geographically prioritised
areas. Therefore, HIV prevention services and potentially PrEP may be needed in these areas.
While population-level HIV incidence, sex and age distributions, and STI prevalence inform
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resource distribution, individual-level data on behaviours and recent history of STI could be
used to prompt PrEP counselling at any service delivery site. This requires the integration of
PrEP and HIV prevention into other health services such as sexual and reproductive health
and antenatal and postnatal care. PrEP services can have wider benefits beyond preventing
HIV infection such as bringing people who have not previously sought HIV testing and have
self-identified as having higher HIV-risk into services. This could result in increased HIV test-
ing, diagnosis, and linkage to treatment for those with HIV alongside access to PrEP for those
at substantial risk. Increasing PrEP availability, uptake, and continuation by individuals at sub-
stantial risk is critical if population-level reductions in HIV infections are to be achieved.
Recent adaptations, some prompted by the Coronavirus disease 2019 (COVID-19) pandemic
restrictions, which simplify PrEP access such as community-based services and telemedicine,
have been well received by PrEP users and have potential for the future [34–36].
Limitations of our approach are that we used modelled estimates of new HIV infections at a
subnational level as it was the only way to estimate age-, sex-, and district-specific measures of
new infections. Estimates of incidence in the HIVE model relied heavily on programmatic
treatment data that had mixed quality; more recent modelling efforts have improved the
review of input data and thus the district-level incidence estimates. The models were calibrated
to 2016 data, and the DHS surveys were from the same period. As overall HIV incidence falls,
the numbers needed to PrEP to prevent a new HIV infection will tend to rise.
We derived our risk estimates for behavioural risk factors from nationally but not subna-
tionally representative HIV data and also from non-longitudinal data. We applied these to
HIV incidence estimates but given that no longitudinal age- and sex-specific risk estimates for
the effect of STI and STINP on HIV incidence were available, we considered the use of PRs
from population-based cross-sectional data to be useful, nonetheless. Furthermore, the survey
data we used to determine STI and NP prevalence were based on self-report and therefore
were likely underestimated since STIs in women are often asymptomatic, and there may be
social desirability bias associated with reporting NPs. Operationalising prioritisation
approaches is likely to also use self-reporting in the medium term. As had been found in most
sexual behaviour surveys, in the selected countries, considerably more men reported non-reg-
ular sexual partnerships in the past 12 months compared with women. Our estimate of PrEP
need would therefore be conservative. We assumed that PrEP efficacy was 100% for this hypo-
thetical PrEP target estimating exercise. Yet PrEP must first reach the intended population and
then must be taken as prescribed to avert new infections. We therefore scaled back the number
of HIV infections averted to allow for a 50% effectiveness. Both coverage of PrEP services and
uptake and continuation on PrEP are currently low in all 3 countries, and therefore, our esti-
mate of infections averted may be optimistic. Furthermore, not all people with risk factors for
HIV need PrEP. Some may choose other prevention options, including consistent condom
use.
We provide a pragmatic approach to allow estimates of the size, incidence, and impact of
offering PrEP to subpopulations by combining geospatial HIV incidence estimates with pub-
licly available population-based risk data. Analyses of this sort can be used to gain an under-
standing of who may benefit from PrEP in a general population setting and may help
countries to consider appropriate numerical targets and population focus for PrEP pro-
grammes. This analysis could also be important for considerations for the introduction of new
biomedical prevention options, such as long-acting PrEP. As more options for PrEP become
available, their strategic introduction will be important. Using 3 countries as examples, we
show that by prioritising risk factors, high-incidence subpopulations can be identified,
although in Malawi, none reached the 3% incidence threshold. This analysis could provide a
starting point for understanding PrEP need, prioritising resources, and focusing services for
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populations beyond key populations in high-HIV-burden countries which are considering or
implementing PrEP.
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